CMP-001 in Combination With Pembrolizumab in Subjects With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Terminated · Phase 2 · NCT04633278
Conditions: Squamous Cell Carcinoma of Head and Neck
At a glance
- Research payments reported, 2025
- $13,207
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 24
About the trial
- Sponsor
- Regeneron Pharmaceuticals
- Tested
- CMP-001 (drug), Pembrolizumab (drug)
- Dates
- Started 2021-01-21; completion 2024-01-19
- Results posted
- Yes
CMP-001-007 is a Phase 2 study of CMP-001 intratumoral (IT) and pembrolizumab intravenous (IV) administered to participants with head and neck squamous cell carcinoma (HNSCC) who have not been previously treated with a programmed cell death protein 1 (PD-1) blocking antibody. The primary objective of the study is to determine the Investigator-assessed confirmed objective response with CMP-001 in combination with pembrolizumab in subjects with head and neck squamous cell carcinoma (HNSCC) The secondary objectives are to: * To evaluate the safety and tolerability of CMP-001 administered by intratumoral (IT) injection in combination with pembrolizumab in subjects with HNSCC * To evaluate the…
From ClinicalTrials.gov, last updated 2025-05-11. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Regeneron Pharmaceuticals, Inc. reported $13,207 in research payments for this study in 2025 (15 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- $11,385
- The University of Chicago $1,822
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.